Skip to content

China Takayasu Arteritis Registry (CTA Registry)

China Takayasu Arteritis Registry (CTA Registry)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02964364
Enrollment
1000
Registered
2016-11-16
Start date
2016-08-31
Completion date
2026-07-31
Last updated
2016-11-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

TAKAYASU ARTERITIS

Keywords

TAKAYASU ARTERITIS

Brief summary

Takayasu arteritis (TA) is a chronic large-vessel vasculitis that mainly affects the aorta and its major branches. The epidemiology and pathophysiology of TA is still unclear in China, although many studies have been done. Our previous study supporting by National Natural Science Foundation of China indicated the cytokines such as hs-CRP, NT-proBNP and tumor necrosis factor-alpha (TNF-α) can be used to monitor TA activity, and HLA gene alleles were associated with TA in Chinese han population. Further investigations with larger samples are needed to fully understand the a pathophysiology of TA. The purpose of this study is to build a Chinese national registry system for TA to obtain real-world information, such as current status of characteristics, diagnosis, disease activity, the severity of disease, treatment and outcomes of Chinese TA patients. To analysis and development of effective disease monitoring and treatment strategies.

Detailed description

Takayasu arteritis (TA) is a chronic vasculitis that causes inflammation of the aorta and its main branches and is characterized by adventitial thickening and cellular infiltration of the tunica media, with local destruction of vascular smooth muscle cells and elastin. The disease is very rare but most commonly occurs in China. In the last decade, the results of our study indicated that HLA-DPB1, HLA-DQA1, HLA-DQB1 and HLA-DRB1 gene alleles were associated with TA in Chinese Han population. And the clinical features of patients with TA were analyzed. The cytokines such as hs-CRP, NT-proBNP and tumor necrosis factor-alpha (TNF-α) can be used to monitor TA activity. But there are still many unknown fields in TA, such as the epidemiology and pathophysiology. This study is to build a Chinese national registry system for TA to obtain real-world information, such as current status of characteristics, diagnosis, disease activity, the severity of disease, treatment and outcomes of Chinese TA patients. To analysis and development of effective treatment strategies.

Interventions

None listed

Sponsors

Aimin Dang
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
5 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Age at disease onset \< 40 years. (Development of symptoms or findings related to Takayasu arteritis at age \<40 years) * Claudication of extremities. (Development and worsening of fatigue and discomfort in muscles of 1 or more extremity while in use, especially the upper extremities) * Decreased brachial artery pulse. (Decreased pulsation of 1 or both brachial arteries) * BP difference \>10 mm Hg. (Difference of \>10 mm Hg in systolic blood pressure between arms) * Bruit audible on auscultation over 1 or both subclavian arteries or abdominal aorta. * Arteriogram abnormality. (Arteriographic narrowing or occlusion of the entire aorta, its primary branches, or large arteries in the proximal upper or lower extremities, not due to arteriosclerosis, fibromuscular dysplasia, or similar causes; changes usually focal or segmental)

Exclusion criteria

* Vessel lesions that could be entirely due to atherosclerosis. * Giant cell arteritis or other infectious forms of large vessel vasculitis.

Design outcomes

Primary

MeasureTime frameDescription
Mortality of the patients with TA10 years (2016-2026)All-caused death at 10 years.

Secondary

MeasureTime frameDescription
The rate of the major cardiac and cerebrovascular events10 years (2016-2026)the major cardiac and cerebrovascular events (MACCE) defined as the composite of all heart failure, all stroke, all myocardial infarction (MI), or any revascularization at 10 years.

Countries

China

Contacts

Primary ContactAimin Dang, MD,PhD
aimindangfw@gmail.com+8610-88322131
Backup ContactNaqiang lv, MD,PhD
lvnaqiang@gmail.com+8610-88322131

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026